Dumas Jacques 4
4 · TETRAPHASE PHARMACEUTICALS INC · Filed Nov 2, 2017
Insider Transaction Report
Form 4
Dumas Jacques
Chief ScientificOfficer
Transactions
- Sale
Common Stock
2017-10-31$6.03/sh−8,750$52,763→ 0 total - Exercise/Conversion
Common Stock
2017-10-31$3.69/sh+8,750$32,288→ 8,750 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2017-10-31−8,750→ 113,750 totalExercise: $3.69Exp: 2027-01-29→ Common Stock (8,750 underlying)
Footnotes (2)
- [F1]The exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2017.
- [F2]Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/31/2021.